Mariano A Garcia-Blanco

This inventor holds 18 USPTO granted patents and 7 published patent applications and 5 EPO patents, primarily in Gene Therapy. Top assignees: Duke University, The University of Texas System, Virxsys Corporation. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mariano A Garcia-Blanco. Retrieved from https://idiyas.com/inventor/mariano-a-garcia-blanco

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 7)

% Patents Active = 66.7

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 119(Granted Patents)

Location History:

Durham, NC (US) (2000 - 2014)
Hillsborough, NC (US) (2016 - 2023)
Galveston, TX (US) (2021 - 2023)

Company Filing History:

The University of Texas System

Case Western Reserve University

patents

5. 2 out of 2

Intronn Holdings, LLC

patents

6. 1 out of 4

Janssen Diagnostics, LLC

patents

7. 1 out of 32

Menarini Silicon Biosystems, Inc.

patents

8. 1 out of 16,048

University of California

patents

9. 1 out of 1,223

Vanderbilt University

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Gene Therapy

Autoimmune Diseases

RNA Trans-Splicing

Interleukin-7 Receptor

Circulating Tumor Cells

Genetic Markers

Alpha-1-Antitrypsin

Phenotypic Screening

Spliceosome

Synthetic Regulation

Tumor Detection

Antibody Gene Transfer

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12359204 - Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer (2025-07-15),

2. 12247206 - Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer (2025-03-11),

3. 12203138 - Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932) (2025-01-21),

4. 11807853 - Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer (2023-11-07),

5. 11567081 - Method of isolating circulating tumor cells (2023-01-31),

6. 11118186 - Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer (2021-09-14),

7. 10961581 - Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932) (2021-03-30),

8. 10161939 - Method of isolating circulating tumor cells (2018-12-25),

9. 9845481 - Synthetic regulation of gene expression (2017-12-19),

10. 9284575 - Synthetic regulation of gene expression (2016-03-15),

11. 8883753 - [object Object] (2014-11-11),

12. 8158344 - Methods and compositions for correlating genetic markers with multiple sclerosis (2012-04-17),

13. 8053232 - Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing (2011-11-08),

14. 7968334 - Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing (2011-06-28),

15. 7879321 - Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production (2011-02-01),

Title: **Inventor Mariano A Garcia-Blanco: Pioneering Innovations in Autoimmune Disease Research**

Introduction

Mariano A Garcia-Blanco is an accomplished inventor based in Durham, NC, with a remarkable portfolio of 16 patents. His groundbreaking work focuses on methods and treatments related to autoimmune diseases and cancer, contributing significantly to advancements in medical science and genetics.

Latest Patents

Garcia-Blanco's latest patents include innovative methods for identifying individuals at a higher risk of developing autoimmune diseases. One notable patent is the method for identifying subjects based on genetic and/or phenotypic screening for epistatic variants in DDX39B and IL7R. This invention outlines a systematic approach to assess a human subject's risk of autoimmune diseases by analyzing biological samples for soluble Interleukin-7 receptor (sIL7R) and RNA Helicase DDX39B levels.

Another significant patent involves modulating therapies using soluble Interleukin-7 receptor (sIL7R) to treat autoimmune disorders and various cancers. This invention presents compositions and methods administering an effective amount of specific oligonucleotides, directly influencing the splicing of the IL7R pre-mRNA, thus impacting the expression of soluble isoforms.

Career Highlights

Garcia-Blanco's career has been marked by his profound contributions to the fields of immunology and genetics. He has been associated with prestigious institutions such as Duke University, where he advanced research in molecular genetics and disease prevention. His work at Virxsys Corporation further exemplifies his dedication to translating scientific discovery into practical medical solutions.

Collaborations

Throughout his career, Garcia-Blanco has collaborated with distinguished colleagues, including Gerard J McGarrity and Madaiah Puttaraju. These partnerships have fostered innovative research initiatives and have played a vital role in the development of his patented technologies.

Conclusion

In conclusion, Mariano A Garcia-Blanco stands out as a leading innovator in the field of autoimmune diseases and cancer treatment. His 16 patents reflect a commitment to advancing medical science and improving patient outcomes. Through his research and collaboration with renowned institutions and colleagues, he continues to make significant strides in understanding and treating complex health issues.

Profile summary based on public USPTO records.